Using Tools as Designed [Letter]

"Using Tools as Designed [Letter]." International Journal of Chronic Obstructive Pulmonary Disease, , pp. 591–592

Disclosure

Dr MeiLan Han reports grants from NIH, grants from COPD Foundation, during the conduct of the study; personal fees for clinical trial with funds paid to institution from AstraZeneca, personal fees and unrestricted funds paid to institution to support a clinical trial from Boehringer Ingelheim, personal fees from GlaxoSmithKline, non-financial support for drug for clinical trial; on a DSMB with fees paid to institution; another clinical trial with funds paid to institution from Novartis, personal fees from Pulmonx, Teva, Verona, Merck, Mylan, clinical trial with funds paid to institution from Sanofi, personal fees from DevPro, Aerogen, Polarian, United Therapeutics, Regeneron, personal fees and stock options from Altesa BioPharma, clinical trial, funds paid to institution from Nuvaira, support for a clinical trial, funds paid to institution from Sunovion, clinical trial, funds paid to institution from Biodesix and Gala Therapeutics, personal fees from Cipla, Chiesi, GSK, stock options from Meissa Vaccines, outside the submitted work. Dr Barry Make reports grants from NHLBI, during the conduct of the study; grants and/personal fees from American Lung Association, Department of Defense, Astra Zeneca, Spiration, Glaxo Smith Kline, Mt. Sinai, Web MD, Novartis, American College of Chest Physicians, Projects in Knowledge, Medscape, Boehringer Ingelheim, Mylan, Third Pole, Eastern Pulmonary Society, Wolters Kluwer Health (Up-To-Date), Optimum Patient Care Global Limited, Integritas Communications, Quintiles, University of Wisconsin, Pearl, and PRIMed, outside the submitted work. Dr Barbara P Yawn reports grants and/or personal fees from NHLBI, PCORI, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, TEVA, Medscape, Talem Health, COPD Foundation, and Pulmonx, outside the submitted work. The authors report no other conflicts of interest in this communication.